$RGNX
REGENXBIO Inc. Stock $rgnx

$rgnx Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000095017024055691 Filed on May 08, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$22.30M	$15.62M
YoY Change	11.6%	-18.37%
Cost Of Revenue	$10.58M	$4.283M
YoY Change	11.65%	4.16%
Gross Profit	$11.72M	$11.34M
YoY Change	11.56%	-24.54%
Gross Profit Margin	52.55%	72.58%
Selling, General & Admin	$18.86M	$18.29M
YoY Change	-20.44%	-19.19%
% of Gross Profit	160.93%	161.31%
Research & Development	$48.87M	$54.84M
YoY Change	-18.4%	-6.28%
% of Gross Profit	417.11%	483.68%
Depreciation & Amortization	$4.051M	$4.180M
YoY Change	-8.66%	0.05%
% of Gross Profit	34.58%	36.86%
Operating Expenses	$48.87M	$54.84M
YoY Change	-41.55%	-6.28%
Operating Profit	-$56.04M	-$63.86M
YoY Change	-23.35%	-3.47%
Interest Expense	$449.0K	$1.973M
YoY Change	-57.12%	-28.38%
% of Operating Profit
Other Income/Expense, Net	$3.048M	$533.0K
YoY Change	191.12%	-202.7%
Pretax Income	-$52.99M	-$63.33M
YoY Change	-26.47%	-5.02%
Income Tax
% Of Pretax Income
Net Earnings	-$52.99M	-$63.33M
YoY Change	-26.47%	-5.02%
Net Earnings / Revenue	-237.67%	-405.39%
Basic Earnings Per Share	-$1.05	-$1.38
Diluted Earnings Per Share	-$1.05	-$1.38
COMMON SHARES
Basic Shares Outstanding	49.26M	44.43M
Diluted Shares Outstanding	50.60M	45.73M

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$290.4M	$338.7M
YoY Change	-9.29%	2.08%
Cash & Equivalents	$57.77M	$113.0M
Short-Term Investments	$232.6M	$225.7M
Other Short-Term Assets	$23.50M	$27.30M
YoY Change	-37.09%	18.67%
Inventory
Prepaid Expenses	$10.02M	$13.59M
Receivables	$22.81M	$15.83M
Other Receivables	$4.821M	$4.702M
Total Short-Term Assets	$346.7M	$395.4M
YoY Change	-8.48%	1.6%
LONG-TERM ASSETS
Property, Plant & Equipment	$124.0M	$127.7M
YoY Change	-38.36%	-9.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$36.94M	$41.81M
YoY Change	-61.24%	-70.5%
Other Assets	$2.946M	$4.217M
YoY Change	-51.61%	-49.13%
Total Long-Term Assets	$222.7M	$233.8M
YoY Change	-26.66%	-34.81%
TOTAL ASSETS
Total Short-Term Assets	$346.7M	$395.4M
Total Long-Term Assets	$222.7M	$233.8M
Total Assets	$569.4M	$629.2M
YoY Change	-16.57%	-15.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$16.36M	$31.36M
YoY Change	40.58%	34.67%
Accrued Expenses	$49.79M	$40.20M
YoY Change	-12.41%	5.74%
Deferred Revenue	$21.00K	$13.00K
YoY Change	-95.31%	-99.01%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$98.27M	$110.2M
YoY Change	-16.64%	-1.92%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$3.526M	$3.485M
YoY Change	-97.78%	-41.75%
Total Long-Term Liabilities	$3.526M	$3.485M
YoY Change	-97.78%	-41.75%
TOTAL LIABILITIES
Total Short-Term Liabilities	$98.27M	$110.2M
Total Long-Term Liabilities	$3.526M	$3.485M
Total Liabilities	$221.1M	$238.5M
YoY Change	-20.06%	-15.61%
SHAREHOLDERS EQUITY
Retained Earnings	-$821.4M	-$768.4M
YoY Change	41.55%	51.2%
Common Stock	$1.172B	$1.162B
YoY Change	17.63%	18.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$348.3M	$390.7M
YoY Change
Total Liabilities & Shareholders Equity	$569.4M	$629.2M
YoY Change	-16.57%	-15.86%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$52.99M	-$63.33M
YoY Change	-26.47%	-5.02%
Depreciation, Depletion And Amortization	$4.051M	$4.180M
YoY Change	-8.66%	0.05%
Cash From Operating Activities	-$45.50M	-$55.46M
YoY Change	-3.86%	-31.47%
INVESTING ACTIVITIES
Capital Expenditures	$474.0K	$557.0K
YoY Change	-81.61%	-88.44%
Acquisitions
YoY Change
Other Investing Activities	$206.0K	$13.74M
YoY Change	-99.64%	-79.77%
Cash From Investing Activities	-$268.0K	$13.18M
YoY Change	-100.49%	-79.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-9.445M	120.7M
YoY Change	3.09%	-1435.9%
NET CHANGE
Cash From Operating Activities	-45.50M	-55.46M
Cash From Investing Activities	-268.0K	13.18M
Cash From Financing Activities	-9.445M	120.7M
Net Change In Cash	-55.21M	78.45M
YoY Change	4260.98%	-392.07%
FREE CASH FLOW
Cash From Operating Activities	-$45.50M	-$55.46M
Capital Expenditures	$474.0K	$557.0K
Free Cash Flow	-$45.97M	-$56.01M
YoY Change	-7.87%	-34.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2024Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	41807000
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	38871000
CY2024Q1	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	523000
CY2023Q4	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	701000
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	127662000
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001590877
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2024Q1	us-gaap	Other Receivable After Allowance For Credit Loss Current Related Party Type Extensible Enumeration OtherReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q4	us-gaap	Other Receivable After Allowance For Credit Loss Current Related Party Type Extensible Enumeration OtherReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-37553
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	REGENXBIO Inc.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-1851754
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	9804 Medical Center Drive
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Rockville
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20850
CY2024Q1	dei	City Area Code CityAreaCode	240
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	552-8181
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2024Q1	dei	Trading Symbol TradingSymbol	RGNX
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	49255966
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	112975000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34522000
CY2024Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	225728000
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	240736000
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15828000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	24790000
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	13590000
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	14520000
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	27297000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	20403000
CY2024Q1	us-gaap	Assets Current AssetsCurrent	395418000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	334971000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	132103000
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	57558000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	60487000
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2030000
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2030000
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4217000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4807000
CY2024Q1	us-gaap	Assets Assets	629215000
CY2023Q4	us-gaap	Assets Assets	573970000
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	31356000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	22786000
CY2024Q1	rgnx	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	33129000
CY2023Q4	rgnx	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	49703000
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	13000
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	148000
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7066000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7068000
CY2024Q1	rgnx	Liability Related To Sale Of Future Royalties Current LiabilityRelatedToSaleOfFutureRoyaltiesCurrent	38615000
CY2023Q4	rgnx	Liability Related To Sale Of Future Royalties Current LiabilityRelatedToSaleOfFutureRoyaltiesCurrent	50567000
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	110179000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	130272000
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	80183000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	82222000
CY2024Q1	rgnx	Liability Related To Sale Of Future Royalties Non Current LiabilityRelatedToSaleOfFutureRoyaltiesNonCurrent	44702000
CY2023Q4	rgnx	Liability Related To Sale Of Future Royalties Non Current LiabilityRelatedToSaleOfFutureRoyaltiesNonCurrent	43485000
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3485000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6249000
CY2024Q1	us-gaap	Liabilities Liabilities	238549000
CY2023Q4	us-gaap	Liabilities Liabilities	262228000
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49043000
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49043000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44046000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44046000
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	5000
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	4000
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1162267000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1021214000
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3229000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4429000
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-768377000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-705047000
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	390666000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	311742000
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	629215000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	573970000
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15622000
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	19138000
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4283000
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4112000
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	54844000
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	58516000
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18291000
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22634000
CY2024Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2101000
CY2024Q1	rgnx	Other Operating Expenses Income OtherOperatingExpensesIncome	34000
CY2023Q1	rgnx	Other Operating Expenses Income OtherOperatingExpensesIncome	-33000
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	79485000
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	85295000
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-63863000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-66157000
CY2024Q1	rgnx	Interest Income From Licencing InterestIncomeFromLicencing	37000
CY2023Q1	rgnx	Interest Income From Licencing InterestIncomeFromLicencing	70000
CY2024Q1	us-gaap	Investment Income Net InvestmentIncomeNet	2469000
CY2023Q1	us-gaap	Investment Income Net InvestmentIncomeNet	2166000
CY2024Q1	us-gaap	Interest Expense InterestExpense	1973000
CY2023Q1	us-gaap	Interest Expense InterestExpense	2755000
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	533000
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-519000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-63330000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-66676000
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1200000
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	3779000
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1200000
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	3779000
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-62130000
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-62897000
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.38
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.38
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.53
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.53
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45733000
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45733000
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43451000
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43451000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	311742000
CY2024Q1	rgnx	Vesting Of Restricted Stock Units VestingOfRestrictedStockUnits	-910000
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	884000
CY2024Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	411000
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	131067000
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9602000
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1200000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-63330000
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	390666000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	516195000
CY2023Q1	rgnx	Vesting Of Restricted Stock Units VestingOfRestrictedStockUnits	-419000
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	471000
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	583000
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11206000
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	3779000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-66676000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	465139000
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-63330000
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-66676000
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	9602000
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	11206000
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4180000
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4178000
CY2024Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	468000
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-682000
CY2024Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	2101000
CY2023Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2024Q1	rgnx	Non Cash Interest Expense NonCashInterestExpense	688000
CY2023Q1	rgnx	Non Cash Interest Expense NonCashInterestExpense	-574000
CY2024Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	71000
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	122000
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-9177000
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-9495000
CY2024Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-930000
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1621000
CY2024Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	6826000
CY2023Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	13651000
CY2024Q1	rgnx	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-1528000
CY2023Q1	rgnx	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-1390000
CY2024Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-590000
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1893000
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	8461000
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-3103000
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-17077000
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-15443000
CY2024Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-135000
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-433000
CY2024Q1	rgnx	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-2041000
CY2023Q1	rgnx	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-1504000
CY2024Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-2764000
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-2849000
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-55455000
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-80918000
CY2024Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	55190000
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0
CY2024Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	68930000
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	67912000
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	557000
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4818000
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	13183000
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	63094000
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	884000
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	471000
CY2024Q1	rgnx	Taxes Paid Related To Net Settlement Of Stock Based Awards TaxesPaidRelatedToNetSettlementOfStockBasedAwards	910000
CY2023Q1	rgnx	Taxes Paid Related To Net Settlement Of Stock Based Awards TaxesPaidRelatedToNetSettlementOfStockBasedAwards	419000
CY2024Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	411000
CY2023Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	583000
CY2024Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	131601000
CY2023Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0
CY2024Q1	rgnx	Offering Expenses Related To At The Market Offering Program OfferingExpensesRelatedToAtTheMarketOfferingProgram	35000
CY2023Q1	rgnx	Offering Expenses Related To At The Market Offering Program OfferingExpensesRelatedToAtTheMarketOfferingProgram	0
CY2024Q1	rgnx	Repayments Under Liability Related To Sale Of Future Royalties RepaymentsUnderLiabilityRelatedToSaleOfFutureRoyalties	11226000
CY2023Q1	rgnx	Repayments Under Liability Related To Sale Of Future Royalties RepaymentsUnderLiabilityRelatedToSaleOfFutureRoyalties	9672000
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	120725000
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-9037000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	78453000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-26861000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	36552000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	98982000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	115005000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	72121000
CY2024Q1	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of Business</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">REGENXBIO Inc. (the Company) is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company's investigational gene therapies use adeno-associated virus (AAV) vectors from its proprietary gene delivery platform (NAV Technology Platform). The NAV</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">®</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Technology Platform consists of exclusive rights to a large portfolio of AAV vectors, including commonly used AAV8 and AAV9. The Company has developed a broad pipeline of gene therapy product candidates using the NAV Technology Platform as a one-time treatment to address an array of diseases. In addition to its internal product development efforts, the Company also selectively licenses the NAV Technology Platform to other leading biotechnology and pharmaceutical companies (NAV Technology Licensees). As of March 31, 2024, the NAV Technology Platform was being applied by NAV Technology Licensees in one commercial product, Zolgensma</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">®</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and in the preclinical and clinical development of a number of other licensed products. Additionally, the Company has licensed intellectual property rights to collaborators for the joint development and commercialization of certain product candidates. The Company was formed in 2008 in the State of Delaware and is headquartered in Rockville, Maryland.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has incurred cumulative losses since inception and as of March 31, 2024, had generated an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">768.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company's ability to transition to recurring profitability is dependent upon achieving a level of revenues adequate to support its cost structure, which depends heavily on the successful development, approval and commercialization of its product candidates. The Company may never achieve recurring profitability, and unless and until it does, the Company will continue to need to raise additional capital. There is no assurance that the Company will be able to raise sufficient capital or obtain financing on favorable terms, or at all. As of March 31, 2024, the Company had cash, cash equivalents and marketable securities of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">380.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which management believes is sufficient to fund operations for at least the next 12 months from the date these consolidated financial statements were issued.</span></p>
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-768400000
CY2024Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	380500000
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities for the periods presented. Management bases its estimates on historical experience and various other factors that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities, and other reported amounts, that are not readily apparent from other sources. Actual results may differ materially from these estimates. Significant estimates are used in the following areas, among others: license and royalty revenue, the allowance for credit losses, accrued research and development expenses and other accrued liabilities, stock-based compensation expense, interest expense under the liability related to the sale of future royalties, income taxes and fair value measurements.</span></p>
CY2024Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reclassifications</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain amounts reported in prior periods have been reclassified to conform to current period financial statement presentation. These reclassifications are not material and have no effect on previously reported financial position, results of operations and cash flows.</span></p>
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	112975000
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	70091000
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2030000
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2030000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115005000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72121000
CY2024Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	269904000
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	37000
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2406000
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	267535000
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	283176000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	149000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3718000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	279607000
CY2024Q1	rgnx	Available For Sale Debt Securities Remaining Maturities Greater Than Three Years AvailableForSaleDebtSecuritiesRemainingMaturitiesGreaterThanThreeYears	0
CY2023Q4	rgnx	Available For Sale Debt Securities Remaining Maturities Greater Than Three Years AvailableForSaleDebtSecuritiesRemainingMaturitiesGreaterThanThreeYears	0
CY2024Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2024Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	90976000
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	170000
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	143582000
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	2236000
CY2024Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	234558000
CY2024Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	2406000
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	38893000
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	66000
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	202585000
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	3652000
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	241478000
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	3718000
CY2024Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	82
CY2024Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	267535000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	279607000
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	189016000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	189311000
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	61354000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	57208000
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	127662000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	132103000
CY2024Q1	rgnx	Impairment Loss Of Property And Equipment Net ImpairmentLossOfPropertyAndEquipmentNet	700000
CY2024Q1	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	1401000
CY2024Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2101000
CY2024Q1	rgnx	Repurchase Of Call Option Amount RepurchaseOfCallOptionAmount	300000000.0
CY2024Q1	rgnx	Percentage Of Common Stock Owned PercentageOfCommonStockOwned	0.0999
CY2024Q1	rgnx	Percentage Of Voting Power PercentageOfVotingPower	0.0999
CY2024Q1	rgnx	Other License And Royalty Revenue OtherLicenseAndRoyaltyRevenue	408000
CY2023Q1	rgnx	Other License And Royalty Revenue OtherLicenseAndRoyaltyRevenue	3013000
CY2024Q1	rgnx	License And Royalty Revenue LicenseAndRoyaltyRevenue	15622000
CY2023Q1	rgnx	License And Royalty Revenue LicenseAndRoyaltyRevenue	19138000
CY2024Q1	rgnx	Milestone Fee Payments Upon Commencement Of Clinical Trials MilestoneFeePaymentsUponCommencementOfClinicalTrials	523900000
CY2024Q1	rgnx	Milestone Fee Payments Upon Submission Of Regulatory Approval Filings MilestoneFeePaymentsUponSubmissionOfRegulatoryApprovalFilings	109800000
CY2024Q1	rgnx	Milestone Fee Payments Upon Achievement Of Specified Sales Targets MilestoneFeePaymentsUponAchievementOfSpecifiedSalesTargets	855000000
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	25491000
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	29586000
CY2024Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	16351000
CY2023Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	20161000
CY2023Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	2000000
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	148000
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1829000
CY2024Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	13000
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1311000
CY2024Q1	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	148000
CY2023Q1	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	930000
CY2024Q1	rgnx	Revenue Recognized Performance Obligation RevenueRecognizedPerformanceObligation	15268000
CY2023Q1	rgnx	Revenue Recognized Performance Obligation RevenueRecognizedPerformanceObligation	18132000
CY2024Q1	rgnx	Aggregate Transaction Price Of License Agreements AggregateTransactionPriceOfLicenseAgreements	900000
CY2024Q1	rgnx	Aggregate Transaction Price Of License Agreements Expected Satisfaction Period AggregateTransactionPriceOfLicenseAgreementsExpectedSatisfactionPeriod	P2Y
CY2024Q1	rgnx	Revenue Recognized Upon Achievement Of Development Milestones RevenueRecognizedUponAchievementOfDevelopmentMilestones	0
CY2023Q1	rgnx	Revenue Recognized Upon Achievement Of Development Milestones RevenueRecognizedUponAchievementOfDevelopmentMilestones	2000000
CY2024Q1	rgnx	Accounts Receivable Table Text Block1 AccountsReceivableTableTextBlock1	<p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounts receivable, net consisted of the following (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.52%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:17.619999999999997%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:17.619999999999997%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current accounts receivable:</span></p></td> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Billed to customers</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">265</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unbilled Zolgensma royalties</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,312</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,128</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_b8c56487-8603-4e64-8f6c-43a540b54c92;"><span style="-sec-ix-hidden:F_5772741c-2ca7-4b61-890d-7c135e42bcbe;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Due from Abeona, net of present value discount</span></span></span></span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,702</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,587</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other unbilled</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">415</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">397</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Allowance for credit losses</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,702</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,587</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current accounts receivable, net</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,828</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,790</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-current accounts receivable:</span></p></td> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other unbilled</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">523</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">701</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-current accounts receivable, net</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">523</span></p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">701</span></p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accounts receivable, net</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,351</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,491</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table>
CY2024Q1	us-gaap	Billed Contract Receivables BilledContractReceivables	101000
CY2023Q4	us-gaap	Billed Contract Receivables BilledContractReceivables	265000
CY2024Q1	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	15312000
CY2023Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	24128000
CY2024Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	4702000
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	4587000
CY2024Q1	rgnx	Other Unbilled Receivables Current OtherUnbilledReceivablesCurrent	415000
CY2023Q4	rgnx	Other Unbilled Receivables Current OtherUnbilledReceivablesCurrent	397000
CY2024Q1	rgnx	Allowance For Credit Losses Current AllowanceForCreditLossesCurrent	4702000
CY2023Q4	rgnx	Allowance For Credit Losses Current AllowanceForCreditLossesCurrent	4587000
CY2024Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	15828000
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	24790000
CY2024Q1	rgnx	Other Unbilled Receivables Non Current OtherUnbilledReceivablesNonCurrent	523000
CY2023Q4	rgnx	Other Unbilled Receivables Non Current OtherUnbilledReceivablesNonCurrent	701000
CY2024Q1	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	523000
CY2023Q4	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	701000
CY2024Q1	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	16351000
CY2023Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	25491000
CY2024Q1	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses	0
CY2023Q1	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses	0
CY2024Q1	rgnx	Due From And To Related Parties Current DueFromAndToRelatedPartiesCurrent	-24575000
CY2023Q1	rgnx	Due From And To Related Parties Current DueFromAndToRelatedPartiesCurrent	-18332000
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9602000
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11206000
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	78800000
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M12D
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9602000
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11206000
CY2024Q1	rgnx	Proceeds From Stock Options Exercised Including Unsettled Options ProceedsFromStockOptionsExercisedIncludingUnsettledOptions	900000
CY2023Q4	rgnx	Percentage Of Reduction In Workforce PercentageOfReductionInWorkforce	0.15
CY2023Q4	us-gaap	Restructuring Charges RestructuringCharges	3700000
CY2024Q1	us-gaap	Restructuring Reserve Period Increase Decrease RestructuringReservePeriodIncreaseDecrease	-300000
CY2023	us-gaap	Restructuring Charges RestructuringCharges	3731000
CY2023	us-gaap	Payments For Restructuring PaymentsForRestructuring	1925000
CY2023Q4	us-gaap	Restructuring Reserve RestructuringReserve	1806000
CY2024Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	1197000
CY2024Q1	us-gaap	Restructuring Reserve Translation And Other Adjustment RestructuringReserveTranslationAndOtherAdjustment	-333000
CY2024Q1	us-gaap	Restructuring Reserve RestructuringReserve	276000
CY2023Q4	rgnx	Accrued Sublicense Fees And Royalties On Reagent Sales AccruedSublicenseFeesAndRoyaltiesOnReagentSales	14234000
CY2024Q1	rgnx	Accrued External General And Administrative Expenses AccruedExternalGeneralAndAdministrativeExpenses	2532000
CY2023Q4	rgnx	Accrued External General And Administrative Expenses AccruedExternalGeneralAndAdministrativeExpenses	2717000
CY2024Q1	rgnx	Accrued Purchases Of Property And Equipment AccruedPurchasesOfPropertyAndEquipment	149000
CY2023Q4	rgnx	Accrued Purchases Of Property And Equipment AccruedPurchasesOfPropertyAndEquipment	386000
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	993000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	458000
CY2024Q1	rgnx	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	33129000
CY2023Q4	rgnx	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	49703000
CY2024Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	200000
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11292000
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10469000
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	27297000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	20403000
CY2024Q1	rgnx	Accrued External Research And Development Expenses AccruedExternalResearchAndDevelopmentExpenses	14508000
CY2023Q4	rgnx	Accrued External Research And Development Expenses AccruedExternalResearchAndDevelopmentExpenses	13762000
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8085000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	18146000
CY2024Q1	rgnx	Accrued Sublicense Fees And Royalties On Reagent Sales AccruedSublicenseFeesAndRoyaltiesOnReagentSales	6862000
CY2023	rgnx	Increase Decrease In Capital Expenditures Incurred But Not Yet Paid IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid	-200000
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1800000
CY2022	rgnx	Increase Decrease In Capital Expenditures Incurred But Not Yet Paid IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid	-800000
CY2024Q1	rgnx	Issuance Costs Of Common Stock Public Offering And Pre Funded Warrants But Not Yet Paid IssuanceCostsOfCommonStockPublicOfferingAndPreFundedWarrantsButNotYetPaid	500000
CY2023Q1	rgnx	Issuance Costs Of Common Stock Public Offering And Pre Funded Warrants But Not Yet Paid IssuanceCostsOfCommonStockPublicOfferingAndPreFundedWarrantsButNotYetPaid	0
CY2024Q1	rgnx	Offering Expenses For Atm Program But Not Yet Paid OfferingExpensesForATMProgramButNotYetPaid	100000
CY2023Q1	rgnx	Offering Expenses For Atm Program But Not Yet Paid OfferingExpensesForATMProgramButNotYetPaid	0

Files In Submission

Name	View Source	Status
rgnx-20240331_htm.xml	Edgar Link	completed
0000950170-24-055691-index-headers.html	Edgar Link	pending
0000950170-24-055691-index.html	Edgar Link	pending
0000950170-24-055691.txt	Edgar Link	pending
0000950170-24-055691-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rgnx-20240331.htm	Edgar Link	pending
rgnx-20240331.xsd	Edgar Link	pending
rgnx-ex31_1.htm	Edgar Link	pending
rgnx-ex31_2.htm	Edgar Link	pending
rgnx-ex32_1.htm	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RGNX
REGENXBIO Inc. Stock $rgnx

2024 Q2 Form 10-Q Financial Statement

#000095017024055691 Filed on May 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGNX REGENXBIO Inc. Stock $rgnx

2024 Q2 Form 10-Q Financial Statement

#000095017024055691 Filed on May 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGNX
REGENXBIO Inc. Stock $rgnx